Navigation Links
Kensey Nash Reports Second Quarter Fiscal Year 2011 Financial Results
Date:2/1/2011

NYSE: STJ), decreased $0.2 million from $4.3 million in the prior fiscal year period.

Partially offsetting these decreases was an increase in general surgery sales, consisting primarily of sales of the Company's new extracellular matrix (ECM) product, the XCM Biologic which is licensed to the Company's strategic partner Synthes.  Sales of ECM products were $1.1 million in the second quarter of fiscal 2011 compared to less than $0.1 million in the prior year comparable quarter, and the Company expects to experience further increases in the second half of the fiscal year as the ECM product sales continue to expand in the U.S. and as the launch outside the U.S. gains momentum.  Offsetting the increase in general surgery sales associated with the ECM products was a decrease in sales of breast biopsy products, which were $0.2 million during the quarter compared to $1.0 million in the prior year comparable quarter due to inventory stocking orders placed in the second quarter fiscal 2010.  Endovascular sales during the quarter were $0.3 million compared to $0.8 million in the prior fiscal year second quarter.

Royalty income for the second quarter of fiscal 2011 was $6.5 million, compared to $6.6 million in the comparable prior fiscal year period. Royalty income in the second quarter of fiscal 2011 included $4.9 million in Angio-Seal™ royalties and $1.4 million in royalties from Orthovita, Inc. (Nasdaq: VITA).  Angio-Seal™ royalties decreased by approximately 2% or $0.1 million in the second quarter of fiscal 2011 compared to the prior fiscal year quarter.  Royalties from Orthovita decreased by approximately 7% or $0.1 million compared to the prior fiscal year period reflecting the impact of the general negative economic conditions in the spine markets.

Earnings Per Share.  Second quarter diluted earnings per share were $0.
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results
2. Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
3. Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product
4. Synthes and Kensey Nash Announce Strategic Agreement for Extracellular Matrix Products
5. Kensey Nash to Present at the 2009 UBS Global Life Sciences Conference
6. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
7. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
8. Par Pharmaceutical Reports Second Quarter 2008 Results
9. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
10. Pharmos Corporation Reports 2008 Second Quarter Results
11. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Aug. 1, 2014 ... the "The World Market for Flow Cytometry ... http://photos.prnewswire.com/prnh/20130307/600769 ... that are now an important component of advanced ... diagnostic instruments for cancer diagnostics, but their newer ...
(Date:8/1/2014)... 2014 The  PROPEL Center  of the  iBIO ... rate of early-stage life sciences companies in ... 15 grants to help Illinois ...   in Chicago .   AdvaMed ... North America , bringing more than 1,000 ...
(Date:8/1/2014)... Cambrex Corporation (NYSE: CBM ) reports results for ... Highlights , Second quarter sales increased 59% to ... year. , Second quarter EBITDA increased 86% to $21.2 ... year (see table at the end of this release). ... of foreign currency, to between 13% and 16% over 2013, ...
(Date:7/31/2014)... July 31, 2014 Today BioSpace , the leading life ... map campaign spotlighting the life sciences community in Illinois ... Kansas , Michigan , Minnesota ... Ohio and Wisconsin . ... percent of all job postings on BioSpace originating in this region in ...
Breaking Biology Technology:The World Market for Flow Cytometry in IVD Applications 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 3iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 4Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16Midwest Biotech Leaders Featured On BioSpace Map 2
... China, July 7 /PRNewswire-Asia-FirstCall/ -- China Clean,Energy Inc. ... "Company"),a producer of biodiesel fuel and environmentally-friendly specialty ... Republic of China,("PRC"), today announced that business conditions ... the first quarter, driven by improved demand and,higher ...
... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... developing breakthrough treatments for human disease, announced today that it ... LX1032 , the company,s oral drug candidate for managing ... LX1032 is designed to reduce serotonin production in patients ...
... The Leukemia & Lymphoma Society (LLS) and The ... initiative to develop stable and immortalized Waldenstrom,s macroglobulinemia (WM) ... researchers to test potential new treatments for the disease. ... lymphoma, characterized by B-lymphocytes in the bone marrow, and ...
Cached Biology Technology:China Clean Energy Provides Business Update 2China Clean Energy Provides Business Update 3Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 2Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 3Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome 4The Leukemia & Lymphoma Society and The International Waldenstrom's Macroglobulinemia Foundation Partner to Develop Cell Lines to Advance Research 2The Leukemia & Lymphoma Society and The International Waldenstrom's Macroglobulinemia Foundation Partner to Develop Cell Lines to Advance Research 3
(Date:7/31/2014)... experimental vaccine protected 100 percent of animal models against ... , which causes an intestinal disease that kills approximately ... print in Infection and Immunity . , ... non-human primates against the purified toxins produced by ... spore infection, a laboratory model that mimics the human ...
(Date:7/31/2014)... how the brain processes speech, potentially increasing the ... at The University of Texas at Dallas. , ... Ear and Hearing , researchers demonstrated for the ... brain,s recognition of speech sounds. , Noise-induced hearing ... affecting an estimated 15 percent of Americans between ...
(Date:7/31/2014)... step has been made to help better identify and treat ... abnormal narrowing and enlarging of medium sized arteries in the ... other organs causing damage. In a new report appearing in ... , scientists provide evidence that that FMD may not be ... show a connection to abnormalities of bones and joints, as ...
Breaking Biology News(10 mins):C. difficile vaccine proves safe, 100 percent effective in animal models 2UT Dallas study reveals effect of loud noises on brain 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
... farming and relieve the pressure on overexploited fish stocks. ... fish escape? Researchers at the University of Gothenburg have ... are urging caution:,-Until further notice transgenic fish should be ... at the Department of Zoology, University of Gothenburg. ...
... A research report featured on the cover of the September ... http://www.fasebj.org ) describes how Australian scientists developed a new gene ... to transport their cargo into our cells. As a result ... cell,s nucleus far more efficiently than in the past, raising ...
... from natural coal deposits in the Gulf of Alaska ... the Exxon Valdez tanker catastrophe. This clearly disproves the ... observed environmental damage. PAH pollutants were blamed for the ... Alaska. Then a dispute erupted over the origins of ...
Cached Biology News:Risks involved with transgenic fish 2Finding the ZIP-code for gene therapy: Scientists imitate viruses to deliver therapeutic genes 2Bioavailable contaminants come from the Exxon Valdez oil catastrophe 2
... a fixative useful for routine procedures. Hollandes ... stable and will decalcify small bone specimens. ... be stained successfully with most stains, and ... red blood cell membranes and cosinophil and ...
Chicken polyclonal antibody to Glutathione-S-Transfrease (GST)...
... the complete enterprise microarray informatics platform for microarray ... Acuity once and use it forever without paying ... Quality Acuity has all the analysis tools ... data, from quality control statistics and normalization, all ...
... As the world of discovery races ever ... you on the fast track. So our constant ... help accelerate your research. Thats why our Biomek ... platform thats as advanced as it is flexible. ...
Biology Products: